Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8791127 | EPI HLTH | Mucosal bioadhesive slow release carrier for delivering active principles |
Mar, 2027
(3 years from now) | |
US8747896 | EPI HLTH | Mucosal bioadhesive slow release carrier for delivering active principles |
Jun, 2027
(4 years from now) | |
US8592434 | EPI HLTH | Mucoadhesive buccal tablets for the treatment of orofacial herpes |
Jun, 2030
(7 years from now) |
Market Authorisation Date: 12 April, 2013
Treatment: Treatment of herpes labialis
Dosage: TABLET;BUCCAL
8
United States
7
European Union
2
Croatia
2
Canada
2
Denmark
2
Spain
2
Portugal
2
Poland
2
Japan
2
China
2
RS
1
Australia
1
Israel
1
IB
1
Korea, Republic of
1
New Zealand
1
Malaysia
1
Austria
1
ME
1
Cyprus
1
Russia
1
Hong Kong
1
Germany
1
Mexico
1
Slovenia
1
Argentina
1
Brazil
1
South Africa
1
Hungary
1
Turkey
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic